Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 10, 2000 - Issue 7
Submit an article Journal homepage
18
Views
18
CrossRef citations to date
0
Altmetric
Review

Novel pharmacotherapies for cocaine abuse 1997 - 2000

Amy Hauck Newman Medicinal Chemistry Section, National Institute on Drug Abuse - Intramural Research Program, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA. [email protected]
Pages 1095-1122 | Published online: 25 Feb 2005

Bibliography

  • GLOWA JA, LESAGE M, STAFFORD D, VOCCI F: Novel for cocaine abuse - 1995 to present. Exp. Opin. Ther. Patents (1997) 7:1459–1476.
  • SELF DW, NESTLER EJ: Molecular mechanisms of drugreinforcement and addiction. Ann. Rev. Neurosci. (1995) 18:463–495.
  • VOLKOW ND, WANG G-J, FOWLER JS et al: Relationshipbetween psychostimulant-induced 'high' and dopamine transporter occupancy. Proc. Natl. Acad. ScL USA (1996) 93:10388–10392.
  • BARDO MT: Neuropharmacological mechanisms ofdrug reward: beyond dopamine in the nucleus accumbens. Grit. Rev. Neurobiol. (1998) 12:37–67.
  • ROCHA BA, FUMAGALLI F, GAINETDINOV RR et al.:Cocaine self-administration in dopamine-transporter knockout mice. Nature Neurosci. (1998) 1:132–137.
  • SORA I, WICHEMS C, TAKAHASHI N et al: Cocainereward models: conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice. Proc. Natl. Acad. ScL USA (1998) 95:7699–7704.
  • KATZ JL, IZENWASSER S, KLINE RH, ALLEN AC, NEWMANAH: Novel 3a-diphenylmethoxytropane analogs: selective dopamine uptake inhibitors with behavioral effects distinct from those of cocaine. J. Pharmacol. Exp. Ther. (1999) 288:302–315.
  • CARROLL Fl, HOWELL LL, KUHAR MJ: Pharmacothera-pies for treatment of cocaine abuse: preclinical aspects. J. Med. Chem. (1999) 42:2721–2736.
  • YOUNG A: Discriminative stimulus profiles of psychoactive drugs. In: Advances in substance abuse (volume 4). Mello N (Ed.), Jessica Kingsley Publishers, London, UK (1991):139–203.
  • MELLO NK, NEGUS SS: Preclinical evaluation ofpharmacotherapies for treatment of cocaine and opioid abuse using drug self-administration procedures. Neuropsychopharmacology (1996) 14:375–424.
  • TZSCHENTKE TM: Measuring reward with the conditioned place preference paradigm: a compre-hensive review of drug effects. Recent progress and new issues. Prog. Neurobiol. (1998) 56:613–672.
  • PICH EM, EPPING-JORDAN MP: Transgenic mice in drug dependence research. Ann. Med. (1998) 30:390–396.
  • BADER M: Transgenic animal models for neurophar-macology. Rev. Neurosci. (2000) 11:27–36.
  • GIROS B, JABER M, JONES SR, WIGHTMAN RM, CARON MG: Hyperlocomotion and indifference to cocaine and amphetamine in ice lacking the dopamine transporter. Nature (1996) 379:606–612.
  • ROCHA BA, SCEARCE-LEVIE K, LUCAS JJ et al.: Increasedvulnerability to cocaine in mice lacking the serotonin-1B receptor. Nature (1998) 393:175–178.
  • WHITE FJ: Cocaine and the serotonin saga. Nature(1998) 393:118–119.
  • WISE RA: Addictive drugs and brain stimulationreward. Ann. Rev. Neurosci. (1996) 19:319–340.
  • KUHAR MJ, RITZ MC, BOJA JW: The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci. (1991) 14:299–301.
  • RITZ MC, LAMB RJ, GOLDBERG SR, KUHAR MJ: Cocainereceptors on dopamine transporters are related to self-administration of cocaine. Science (1987) 237:1219–1223.
  • ROBERTS DCS, RANALDI R: Effects of dopaminergicdrugs on cocaine reinforcement. Clin. Neuropharmacol (1995) 18:S84–S95.
  • AMARA SG, SONDERS MS: Neurotransmitter transporters as molecular targets for addictive drugs. Drug Alcohol Depend. (1998) 51:87–96.
  • SMITH MP, HOEPPING A, JOHNSON KM, TRZCINSKA M,KOZIKOWSKI AP: Dopaminergic agents for the treatment of cocaine abuse. Drug Disc. Today (1999) 4:322–332.
  • WOOLVERTON WL: Cocaine self-administration: pharmacology and behavior. NIDA Res. Monograph (1992) 124:189–202.
  • WINGER G: Preclinical evaluation of pharmacothera-peutics for cocaine abuse. In: Cocaine Abuse Behavior, Pharmacology and Clinical Applications. Higgins ST, Katz JL (Ed.), Academic Press, San Diego, USA (1998):135–158.
  • ROTHMAN RB, GLOWA JR: A review of the effects of dopaminergic agents on humans, animals and drug-seeking behavior and its implications for medication development. Mol. Neuropharm. (1995) 11:1–19.
  • GRABOWSKI J, ROACHE JD, SCHMITZ JM et al.: Replace-ment medication for cocaine dependence: methylphenidate. Clin. Psychopharm. (1997) 17:485–488.
  • WARNER EA, KOSTEN TR, O'CONNOR PG: Pharmaco-therapy for opioid and cocaine abuse. Med. Clin. North Am. (1997) 81:909–925.
  • KOOB GF, CAINE SB: Cocaine addiction therapy - are we partially there? Nature Med. (1999) 5:993–995.
  • PILLA M, PERACHON S, SAUTEL F et al.: Selective inhibi-tion of cocaine seeking behaviour by a partial dopamine D3 receptor agonist. Nature (1999) 400:371–375.
  • CUNNINGHAM KA, CALLAHAN PM: Neurobehavioral pharmacology of cocaine: role for serotonin in its locomotor and discriminative stimulus effects. NIDA Res. Monograph (1994) 145:40–66.
  • HOWELL LL, BYRD LD: Serotonergic modulation of the behavioral effects of cocaine in the squirrel monkey. J. Pharmacol. Exp. Ther. (1995) 275:1551–1559.
  • CALLAHAN PM, CUNNINGHAM KA: Modulation of the discriminative stimulus properties of cocaine: comparison of the effects of fluoxetine with 5-HT1A and 5-HT1s receptor agonists. Neuropharmacology (1997) 36:378–381.
  • MENDELSON JH, MELLO NK: Management of cocaine abuse and dependence. N. Engl. J. Med. (1996) 334:965–972.
  • TECH SK, MELLE NK, MENDELSON JH, KUEHNLE J, GASTFRIEND DR: Buprenorphine effects on heroin-and cocaine-induced subjective responses by drug dependent men. J. Clin. Pharmacol (1994) 14:15–77.
  • SCHOTTENFELD RS, PAKES J, ZIEDONIS D, KOSTEN TR: Buprenorphine: dose-related effects on heroin - and cocaine-abusing opioid dependent humans. Biol. Psychiatry (1993) 34:66–74.
  • KUZMIN AV, SEMENOVE S, GERRITS JMVR: Kappa-opioid receptor agonist U50,48811 modulates cocaine and morphine self-administration in drug naive rats and mice. Eur.J. Pharmacol. (1997) 321:265–271.
  • KUZMIN AV, GERRITS MA, VAN REE JM: Kappa-opioid receptor blockade with nor-binaltorphimine modulates cocaine self-administration in drug-naive rats. Eur. J. Pharmacol. (1998) 358:197–202.
  • MATTES CE, LYNCH TJ, SINGH A et al.: Therapeutic use of butyrlcholinesterase for cocaine intoxication. Toxicol. Appl. Pharmacol. (1997) 145:372–380.
  • KALIVAS PW, NAKAMURA M: Neural systems for behavioral activation and reward. Curr. Opin. Neurobiol. (1999) 9:223–227.
  • SHOAIB M, SWANNER LS, BEYER CE, GOLDBERG SR, SCHINDLER CW: The GABAB agonist baclofen modifies cocaine self-administration in rats. Behav. Pharmacol. (1998) 9:195–206.
  • ROBERTS DCS, ANDREWS MM, VICKERS GJ: Baclofen attenuates the reinforcing effects of cocaine in rats. Neuropsychopharmacology (1996) 15:417–423.
  • DEWEY SL, MORGAN AE, ASHBY CR et al.: A novel strategy for the treatment of cocaine addiction. Synapse (1998) 30:119–129.
  • MOLINA PE, AHMED N, AJMAL M et al.: Co-administration of gamma-vinyl GABA and cocaine: preclinical assessment of safety. Life Sci. (1999) 65:1175–1182.
  • WANG JQ, MCGINTY JF: Glutamate-dopamine interac-tions mediate the effects of psychostimulant drugs. Addiction Biol. (1999) 4:141–150.
  • WITKIN JM: Pharmacotherapy of cocaine abuse: preclinical development. Neurosci. Biobehav. Rev. (1994) 18:121–142.
  • DEBONNEL G, DEMONTIGNY C: Modulation of NMDAand dopaminergic neurotransmission by sigma ligands: possible implications or the treatment of psychiatric disorders. Life ScL (1996) 58:721–734.
  • MCCRACKEN KA, BOWEN WD, MATSUMOTO RR: Novelsigma receptor ligands attenuate the locomotor and stimulatory effects of cocaine. Eur. J. Pharmacol (1999) 365:35–38.
  • MCCRACKEN KA, BOWEN WD, DECOSTA BR, MATSUMOTO RR: Two novel sigma receptor ligands, BD1047 and LR172 attenuate cocaine-induced toxicity and locomotor activity. Eur. J. Pharmacol. (1999) 370:225–232.
  • FATTORE L, MARTELLOTTA MC, COSSU G, MASCIA MS,FRATTA W: CBI cannabinoid receptor agonist WIN 55,212-2 decreases intravenous cocaine self-administration in rats. Behav. Brain Res. (1999) 104:141–146.
  • MCCARTHY JR, HEINRICHS SC, GRIGORIADIS DE: Recentadvances with the CRP( receptor: design of small molecule inhibitors, receptor subtypes and clinical indications. Curr. Pharm. Des. (1999) 5:289–315.
  • SHAHAM Y, ERB S, LEUNG S, BUCZEK Y, STEWART J:CP-154,526, a selective, nonpeptide antagonist of the corticotropin releasing factori receptor attenuates stress-induced relapse to drug seeking in cocaine- and heroin trained rats. Psychopharmacology (Berlin) (1998) 137:184–190.
  • KUHAR MJ, VECHIA SED: CART peptides: novel addiction- and feeding-related neuropeptides. Trends Neurosci. (1999) 22:316–320.
  • ADAM LD, GONG W, VECHIA SD, HUNTER RG, KUHARMJ: CART: from gene to function. Brain Res. (1999) 848:137–140.
  • KUZMIN A, ZVARTAU E, GESSA GL, MARTELLOTTA MC, FRATTA W: Calcium antagonists isradipine and nimodipine suppress morphine intravenous self-administration in drug-naive mice. Pharmacol. Biochem. Behav. (1992) 41:497–500.
  • LUTWICK LI: Unconventional vaccine targets. New Vaccines New Vaccine Technol. (1999) 13:245–264.
  • CORNISH JW, O'BRIEN CP: Developing medications to treat cocaine dependence: a new direction. Curr. Opin. Psychiatry (1998) 11:249–251.
  • CARRERA MRA, ASHLEY JA, PARSONS LH, WIRSCHING P, KOOB GF, JANDA KD: Suppression of psychoactive effects of cocaine by active immunization. Nature (1995) 378:727–730.
  • FOX BS, KANTAK KM, EDWARDS MA et al: Efficacy of a therapeutic cocaine vaccine in rodent models. Nature Med (1996) 2:1129–1132.
  • FOX BS: Development of a therapeutic vaccine for the treatment of cocaine addiction. Drug Alcohol Depend. (1997) 48:153–158.
  • WISE RA, RANALDI R: Cocaine vaccines revisited. Nature Med (1996) 2:1073–1074.
  • METS B, WINGER G, CABRERA C et al.: A catalytic antibody against cocaine prevents cocaine's reinforcing and toxic effects in rats. Proc. Natl. Acad. ScL USA (1998) 95:10176–10181.
  • CARROLL Fl, SCHEFFEL U, DANNALS RF, BOJA JW, KUHAR MJ: Development of imaging agents for the dopamine transporter. Med. Res. Rev. (1995) 15:419–444.
  • ERNST M, LONDON ED: Brain imaging studies of drug abuse: therapeutic implications. Sem. Neurosci. (1997) 9:120–130.
  • FOWLER JS, VOLKOW ND: PET imaging studies in drugabuse. Clin. Toxicol. (1998) 36:163–174.

Websites

  • Drug abuse and addiction research - 25 years of discovery to advance the health of the public. The Sixth Triennial Report to Congress from the Secretary of Health and Human Services. (September 1999): www.nida.nih.gov and references therein.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.